Minocycline Does Not Decrease Geographic Atrophy Enlargement in AMD
By Elana Gotkine HealthDay Reporter
MONDAY, March 25, 2024 -- Oral minocycline is not associated with a decrease in geographic atrophy (GA) enlargement in patients with age-related macular degeneration (AMD), according to a study published online March 14 in JAMA Ophthalmology.
Tiarnan D. L. Keenan, B.M., B.Ch., Ph.D., from the National Eye Institute at the National Institutes of Health in Bethesda, Maryland, and colleagues conducted a phase 2, prospective, single-arm, nonrandomized trial to examine the safety and possible anatomic efficacy of oral minocycline, a microglial inhibitor, for the treatment of GA in AMD. Patients with GA from AMD in one or both eyes were recruited; they began 100 mg oral minocycline twice daily for three years after a nine-month run-in phase. Thirty-seven patients were enrolled and 36 initiated treatment.
The researchers found that 58 percent of the participants completed at least 33 months of treatment and 15 patients discontinued treatment. The mean square root GA enlargement rate in study eyes was 0.31 and 0.28 mm per year during the run-in and treatment phases, respectively. No difference was seen between the two phases in the secondary outcome measure of GA enlargement rate. Among 32 participants, there were 129 treatment-emergent adverse events recorded; 38 percent were related to minocycline.
"Given the potential disadvantages of existing therapeutic approaches, additional strategies remain desirable," the authors write. "It may be necessary to elucidate more clearly the pathogenetic mechanisms underlying GA incidence and progression to develop therapies that target the underlying disease processes."
Several authors disclosed ties to the pharmaceutical and medical device industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Home Vision Tests Offer Limited Diagnostic Accuracy for Neovascular AMD
MONDAY, April 29, 2024 -- No home-monitoring vision test has the diagnostic accuracy of hospital eye service follow-up clinics to identify active neovascular age-related macular...
Burden of Visual Impairment Has Increased Globally
TUESDAY, Dec. 12, 2023 -- The number of prevalent cases of visual impairment globally increased substantially in working-age individuals from 1990 to 2019, according to a study...
AI Model Can Respond Appropriately to Ophthalmology Questions
FRIDAY, Aug. 25, 2023 -- Large language models (LLMs) like ChatGPT can respond to patient-written ophthalmology questions and usually generate appropriate responses, according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.